Skip to main content

Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team

Course Description

In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.


John L. Marshall, MD

Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
  • Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach